Imatinib mesylate (STI571, Gleevec) is a selective inhibitor of the tyrosine kinases BCR-ABL, c-KIT and PDGF-R and has been shown to be highly active in chronic myeloid leukemia (CML) and has significant antitumor efficacy against gastrointestinal stroma tumors (GIST). The gene discussed is PDGFRB; the disease is gastrointestinal stromal tumor.